Agenus Reports Third-Quarter 2026 Results and BOT+BAL Authorizations
Agenus reported third-quarter 2026 results, with first marketing authorizations for BOT+BAL. The Phase 3 ROBBIN study remains on track for first patient enrollment in Q1 2027, with strong global investigator engagement.